The United States (US) has agreed to purchase additional doses of coronavirus disease 2019 (COVID-19) vaccine from Pfizer/BioNTech and Moderna.

Pfizer/BioNTech will supply the US government with an additional 100 million doses, bringing the total supplied to 300 million.  Under the Emergency Use Authorization (EUA), the BNT162b2 vaccine is administered intramuscularly as a 2-dose series spaced 21 days apart and is authorized for use in individuals 16 years of age and older.

“It is our objective to supply as many doses of our COVID-19 vaccine as possible to people in order to help end this pandemic, reduce the hospitalization of especially elderly people and bring us back to our normal lives,” said Ugur Sahin, MD, CEO and Co-founder of BioNTech.

Similarly, the US government has purchased another 100 million doses of Moderna’s COVID-19 vaccine, bringing the order to 300 million doses. To date, the Company has already supplied the US with 41 million doses. According to the Centers for Disease Control and Prevention, 22 million people have received the vaccine. The first 100 million doses are on track to be delivered in the first quarter, with another 100 million by May 2021.  The mRNA-1273 vaccine is administered intramuscularly as a series of 2 doses, given 28 days apart, and is authorized for individuals 18 years of age and older.


Continue Reading

“We appreciate the confidence that the US government has demonstrated in our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We continue to scale up our manufacturing capability, both in and outside of the United States.”

References

1.      Pfizer and BioNTech to supply the United States with 100 million additional doses of COVID-19 vaccine. [press release]. New York, USA, Mainz, Germany; Pfizer and BioNTech: February 12, 2021.

2.      US government purchases additional 100 million doses of Moderna’s COVID-19 vaccine. [press release]. Cambridge, MA; Moderna: February 11, 2021.